ReviewJournal of thrombosis and thrombolysis2015
Anticoagulation therapy in 2015: where we are and where we are going.
Review in Journal of thrombosis and thrombolysis, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Standardized use of novel oral anticoagulants plasma level thresholds in a new thrombolysis decision making protocol.Journal of thrombosis and thrombolysis · 2016Trial
- Article
- Measuring residual anti-Xa activity of direct factor Xa inhibitors after reversal with andexanet alfa.International journal of laboratory hematology · 2021Article
- Barriers and facilitators for optimizing oral anticoagulant management: Perspectives of patients, caregivers, and providers.PloS one · 2021Article
- Reversal of direct oral anticoagulants.Vascular health and risk management · 2017Review
- Pathways for outpatient management of venous thromboembolism in a UK centre.Thrombosis journal · 2016Review
- Modulation of the Coagulation Cascade Using Aptamers.Arteriosclerosis, thrombosis, and vascular biology · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Oral anticoagulants are a mainstay for the prevention and treatment of venous and arterial thrombosis. In 2015, the non-vitamin K oral anticoagulants (NOACs) are already replacing warfarin for many indications. Ongoing studies are focused on development of antidotes and specific reversal agents for the NOACs, and assessing their utility for prevention of cardiovascular events in patients with heart failure, coronary or peripheral artery disease, or embolic stroke of unknown source. This paper (a) lists the current indications for the NOACs; (b) reviews the current impact of the NOACs in each of these indications;
Indexed as
Identifiers
25698404What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.